EJPMR, 2026, 13(8), 125-133 **Review Article** **Impact Factor: 8.158**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211
ISSN (P): 3051-2573
Coden USA: EJPMAG

RECENT ADVANCES IN SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEMS (SNEDDS) FOR IMPROVING THE ORAL BIOAVAILABILITY OF POORLY WATER-SOLUBLE DRUGS: A REVIEW

Praveenkumar M.[1]*, Sundaramoorthy K.[2]

[1]M. Pharm., (PG Scholar)[1]*, [2]Head of Department
Department of Pharmaceutics, Adhiparasakthi College of Pharmacy, Melmaruvathur-603 319, Affiliated to The Tamil Nadu Dr. M.G.R Medical university, Chennai 600 032, Tamil Nadu, India.

***Corresponding Author: Praveenkumar M.**

M. Pharm., (PG Scholar), Department of Pharmaceutics, Adhiparasakthi College of Pharmacy, Melmaruvathur-603 319, Affiliated to The Tamil Nadu Dr. M.G.R Medical university, Chennai 600 032, Tamil Nadu, India.

DOI: https://doi.org/10.5281/zenodo.21702787

How to cite this Article: Praveenkumar M.[1]*, Sundaramoorthy K.[2]. (2026). Recent Advances In Self-Nanoemulsifying Drug Delivery Systems (Snedds) For Improving The Oral Bioavailability Of Poorly Water-Soluble Drugs: A Review. European Journal of Pharmaceutical and Medical Research, 13(8), 125–133.

Article Received on 01/07/2026 **Article Revised on 22/07/2026** **Article Published on 01/08/2026**

ABSTRACT

Poorly water-soluble drugs remain a major challenge in oral drug delivery because of their low aqueous solubility and slow dissolution, which can reduce oral bioavailability. Several formulation approaches have been developed to overcome these limitations, among which Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) have gained considerable attention. SNEDDS are lipid-based formulations composed of oils, surfactants, and co-surfactants that spontaneously form fine oil-in-water nanoemulsions after contact with gastrointestinal fluids under gentle agitation. This property improves drug dissolution, enhances drug absorption, and may increase oral bioavailability. The present review discusses the fundamental principles of SNEDDS, Selection of formulation components, mechanism of self-emulsification, formulation development, and commonly used characterization techniques. In addition, recent advances in liquid and solid SNEDDS, their pharmaceutical applications for poorly water-soluble drugs, and current challenges are summarized. The review also highlights the potential of SNEDDS as an effective and versatile lipid-based drug delivery system for improving the therapeutic performance of poorly water-soluble drugs and outlines future directions for research and development.

KEYWORDS: Self-Nanoemulsifying Drug Delivery System, SNEDDS, Poorly Water-Soluble Drugs, Lipid-Based Drug Delivery, Oral Drug Delivery, Solubility Enhancement.

1. INTRODUCTION

1.1 The Solubility Challenge in Oral Drug Delivery

Taking medicines through the mouth is the most common and preferred route in the pharmaceutical industry. It is highly convenient for patients, easy to manufacture in large batches, and does not require painful injections. However, drug discovery teams face a massive bottleneck today. More than 40% of newly discovered active pharmaceutical ingredients (APIs) do not dissolve properly in water. According to the Biopharmaceutical Classification System (BCS), these poorly soluble molecules are placed into two major groups:

- **BCS Class II:** Molecules with low solubility but high membrane permeability.
- **BCS Class IV:** Molecules with both low solubility and low membrane permeability.

When a patient swallows these hydrophobic drugs, the chemical particles cannot break down easily in the stomach acid or intestinal fluids. Because a drug must be in a completely dissolved state before the body can absorb it, this slow dissolution rate acts as a strict barrier. Consequently, these medications show highly erratic, unpredictable, and poor oral absorption profiles. To get enough drug into the blood to show a therapeutic action, doctors are often forced to prescribe higher doses. Unfortunately, taking higher doses increases the risk of toxic side effects and causes poor patient compliance. Therefore, finding a reliable carrier system that keeps

hydrophobic drug structures completely dissolved inside the gastrointestinal tract is a major goal in modern formulation science.

1.2 Limitations of Traditional Solubilization Techniques

To solve these tough dissolution problems, traditional formulation laboratories usually try standard physical methods. These methods include breaking the drug down into micro-particles (micronization), mixing the drug with cyclodextrin carriers (complexation), or dispersing the drug into solid polymer matrices (solid dispersions). While these old methods can improve dissolution to some extent, they have serious practical flaws:

- **Particle Agglomeration:** Making the drug particles extremely fine often creates static charges, causing the particles to stick back together.
- **Physical Instability:** Solid dispersions are notorious for being unstable during storage, meaning the amorphous drug can shift back into an unabsorbable crystalline form.
- **First-Pass Metabolism:** These traditional methods do not protect the active drug molecule from being quickly destroyed by liver enzymes before it even circulates through the rest of the body.

1.3 Introduction to SNEDDS Technology

To completely bypass the limitations of crystalline drug dissolution, lipid-based nano-formulations have become a highly successful alternative. Among these systems, Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) stand out as a premier choice. Technically, SNEDDS are clear, isotropic liquid mixtures that remain completely stable over long periods. They are prepared by blending three main parts:

- Natural or synthetic lipophilic oils.
- Strong surfactants that mix well with water.
- Matching co-surfactants or organic co-solvents.

Inside this unique liquid matrix, the active drug molecule is completely dissolved from the start. This means the drug stays in a molecularly dispersed, non-crystalline state long before the patient takes the medication.

1.4 Advantages and Disadvantages of SNEDDS

While designing self-nanoemulsifying systems offers a powerful solution for delivery challenges, formulators must balance the operational benefits against clear technical limitations before moving to large-scale production.

1.4.1 Advantages

Rapid Action: Formulations disperse instantly in gastric fluids, bypassing the slow dissolution step entirely to provide faster therapeutic action.

Enhanced Bioavailability: The massive surface area of sub-200 nm lipid droplets ensures maximum exposure to the absorption window of the intestinal wall.

Protection of Active Ingredients: The outer surfactant-stabilized oil layer shields sensitive drug structures from structural degradation by chemical attack or harsh gastric pH levels.

Dose Reduction: Higher absorption efficiency allows clinical teams to lower the total amount of active drug administered, lowering the risk of patient side effects.

1.4.2 Disadvantages

Chemical Leakage Risks: Liquid concentrates can sometimes react with capsule materials during long-term storage, leading to soft gelatin softening or leaking.

High Surfactant Load: Incorporating high concentrations of surfactants can occasionally cause localized irritation to the patient's stomach lining if not carefully optimized.

Risk of Precipitation: If the aqueous phase dilutes the system too heavily inside the body, the drug might crash out into an unabsorbable crystalline form.

Production Costs: Purchasing specialized semi-synthetic lipid components and handling advanced porous carriers increases the overall manufacturing cost.

2. COMPONENTS OF SNEDDS

The clinical success of a self-nanoemulsifying system depends entirely on choosing the right chemical ingredients. A standard SNEDDS formula is not a simple random blend. It requires a precise combination of an oil phase, a primary surfactant, and a co-surfactant or co-solvent.

2.1 Lipid Phase (Oils)

The oil phase is the most important part of the formulation. It dissolves the hydrophobic drug and carries it through the digestive tract. The amount of drug you can put into the SNEDDS depends directly on how well the drug dissolves in the selected oil. Additionally, the type of oil determines how the body absorbs the drug and whether it can travel through the lymphatic system. Formulators group these oils into three main categories based on their chemical structure:

- **Long-Chain Triglycerides (LCT):** Examples include corn oil, olive oil, and soybean oil. LCTs are excellent choices if you want to push the drug into the lymphatic system. Their long carbon chains trigger the production of chylomicrons in the intestine. However, highly crystalline drugs sometimes show limited solubility in raw LCTs.
- **Medium-Chain Triglycerides (MCT):** Examples include coconut oil derivatives, Captex 355, and Miglyol 812. MCTs are highly popular in research laboratories. They do not spoil easily through oxidation, they emulsify much faster than LCTs, and they dissolve a wide variety of lipophilic drugs.
- **Semi-Synthetic Lipids:** Examples include Labrafil M 1944CS and Maisine CC. These are chemically modified oils that contain partial glycerides. Because of their unique structure, they possess natural self-emulsifying properties, which helps stabilize the final nanoemulsion.

2.2 Surfactants

Surfactants are specialized molecules that lower the surface tension between the oil droplets and the surrounding stomach water. This lowering of tension allows the emulsion to form instantly with very little physical effort. To create a stable oil-in-water (o/w) nanoemulsion, formulators must choose non-ionic surfactants with a high Hydrophilic-Lipophilic Balance (HLB) value, usually above 12.

Common choices include Polysorbate 80 (Tween 80), Kolliphor EL, and Kolliphor RH40. Scientists prefer non-ionic surfactants over ionic ones for two main reasons: they do not irritate body tissues and they remain highly stable even when the pH or salt levels change in the stomach and intestines. However, using too much surfactant can hurt the stomach lining, so the amount must be kept as low as possible.

2.3 Co-surfactants and Co-solvents

In most cases, a single surfactant cannot lower the surface tension enough to bring the droplet size below 200 nm. Therefore, formulators add a co-surfactant or co-solvent to help. Short-chain alcohols and glycols, like ethanol, propylene glycol, PEG 400, and Transcutol P, are widely used.

These smaller molecules wedge themselves between the primary surfactant molecules at the droplet boundary. This action makes the film around the oil droplets highly flexible, allowing it to bend easily into tiny nano-droplets. Co-solvents also help dissolve larger amounts of both the drug and the main surfactant in the initial liquid mix, preventing the drug from crashing out or precipitating when it first hits gastric fluids.

2.4 Construction of Pseudoternary Phase Diagrams

Before mixing the final formulation, researchers must find the exact concentration boundaries where spontaneous emulsification can actually take place. To map out this working zone, formulators build triangular graphs called pseudoternary phase diagrams. These special diagrams plot three distinct components against each other: the pure oil phase, the surfactant, and the co-surfactant or co-solvent.

To keep the triangular graph easy to read, the surfactant and co-surfactant are pre-mixed at fixed weight ratios such as 1:1, 2:1, or 3:1. This Smix combination acts as one single corner of the triangle, while the other two corners represent the pure oil phase and the water phase (or simulated gastric fluids).

Formulators perform water titration tests by slowly dropping water into different weight blends of the oil and Smix. The mixture is stirred gently at 37°C match human body temperature. After adding each drop of water, the physical appearance of the container is carefully checked by eye.

Nanoemulsion Zone: Clear, transparent, or slightly bluish fluid mixtures mean the system successfully broke down into sub-200 nm droplets. These coordinates are marked inside the working nanoemulsion region on the graph.

Failure Zone: Milky, cloudy, or completely phase-separated mixtures mean the droplets are too large or unstable.

Mapping these boundary points creates a distinct self-emulsifying region on the triangular plot. A larger area on the diagram means the chosen formulation is highly robust and will remain stable even when diluted heavily by different fluid volumes inside the human stomach.

3. PREPARATION OF LIQUID SNEDDS

Developing a liquid SNEDDS formulation in a laboratory setup is a straightforward process. Compared to solid nanostructures like liposomes or solid lipid nanoparticles, liquid SNEDDS are much easier to compound. The formulation technique does not require heavy machinery, high-pressure homogenizers, or complex organic solvent evaporation steps. Instead, it relies on a simple, systematic liquid blending method.

3.1 Screening and Component Selection

Before mixing the components, formulators must identify the correct ratio of ingredients. The selection process involves a series of basic screening steps:

Saturation Solubility Studies: An excess amount of the targeted poorly soluble drug is added into separate vials containing pure oils, surfactants, and co-surfactants. These vials are kept in a water bath shaker at room temperature or 37°C for 48 to 72 hours. The mixtures are then centrifuged, and the clear supernatant is analyzed using UV-Visible spectroscopy or HPLC. The components that dissolve the highest amount of the drug are chosen.

Surfactant Mix Optimization: The chosen surfactant and co-surfactant are blended together at specific fixed weight ratios, such as 1:1, 2:1, or 3:1. This blend is commonly referred to as the Smix.

3.2 Blending Procedure

Once the individual components are screened and selected, the actual preparation of the liquid concentrate follows these physical steps:

Step 1 (Accurate Weighing): The precise amount of the hydrophobic active pharmaceutical ingredient (API) is accurately weighed using a digital analytical balance.

Step 2 (Oil and Smix Incorporation): The required quantity of the selected lipophilic oil phase is added into a clean glass vial. Next, the optimized Smix combination is introduced into the same vial at a specific predetermined ratio (for example, an oil-to-Smix ratio of 1:9, 2:8, or 3:7)

Step 3 (Thermodynamic Melting & Mixing): The glass vial containing the oil, Smix, and the drug is placed on a digital magnetic stirrer. A small magnetic bead is dropped inside the vial. The stirring speed is adjusted

gently, and the temperature is maintained between 37°C and 50°C. Heating helps lower the viscosity of the lipids and accelerates the dissolution of the drug crystals.

Step 4 (Equilibration): The stirring process is continued until the drug particles dissolve completely, forming a single, clear, isotropic liquid phase. Once the solution looks uniform, the formulation is removed from the stirrer and cooled down to room temperature.

The final liquid SNEDDS concentrate is stored safely in sealed amber glass vials to protect the lipid components from potential photo-oxidation. The batch is kept undisturbed for at least 24 hours to check for any unexpected drug precipitation or phase separation before proceeding to testing.

4. CHARACTERIZATION AND EVALUATION OF LIQUID SNEDDS

To confirm that a liquid SNEDDS formulation will perform reliably inside the human body, the prepared isotropic mixture must pass a series of strict quality control tests. Because the concentrate is designed to form a nanoemulsion inside the digestive tract, both the raw liquid and its diluted form are carefully evaluated.

4.1 Visual Assessment and Phase Clarity

The simplest way to check if a system emulsifies properly is through visual evaluation. A small sample of the liquid SNEDDS concentrate (usually 1 mL) is added to a beaker containing 100 mL of distilled water or simulated gastric fluid (0.1N HCl) maintained at 37°C. The mixture is stirred gently using a magnetic stirrer to simulate stomach movement.

The resulting dispersion is classified using a standard grading system:

Grade A: Spontaneously forms a clear, transparent, or slightly bluish nanoemulsion within less than 1 minute.

Grade B: Spontaneously forms a slightly less clear, translucent, or bluish-white emulsion within 1 to 2 minutes.

Grade C: Forms a milky, opaque white emulsion within 2 minutes, indicating larger droplet dimensions.

Grade D: Shows poor emulsification with visible oil droplets floating on the surface of the water.

4.2 Self-Emulsification Time

The speed at which a liquid SNEDDS breaks down under mild biological movement is a direct indicator of its structural efficiency. Formulators measure this parameter using a standard USP Type II dissolution apparatus. A specific volume of the liquid concentrate (typically 1 mL) is carefully introduced into 250 mL of simulated gastric fluid 0.1 N HCl or distilled water maintained at a strict physiological temperature of 37°C. The paddle rotation speed is set at a low agitation rate, usually around 50 rpm, to mimic natural stomach contractions. The exact time required for the isotropic oil droplet mass to disperse completely into a uniform, clear nanostructure is recorded using a digital stopwatch. A high-performing system should achieve complete spontaneous emulsification within less than 60 seconds.

4.3 Percentage Transmittance Measurement

To quantitatively support the initial visual grading data, researchers verify the absolute optical clarity of the reconstituted nanoemulsion by measuring its percentage transmittance. The liquid SNEDDS concentrate is first diluted 100 times with distilled water. A sample of this diluted mixture is transferred into a quartz cuvette, and its light transmission behaviour is analysed using a UV-Visible spectrophotometer set at a specific wavelength of 638 nm. Distilled water is processed as the 100% blank baseline reference standard. An optimized SNEDDS mixture that breaks down into ideal nano-sized droplets will yield a transmittance value cleanly exceeding 95%, confirming that the particles are small enough to allow light to pass through without scattering.

4.4 Droplet Size and Polydispersity Index (PDI)

Droplet size analysis is the most critical evaluation test for SNEDDS. It directly correlates with the surface area available for drug release. The liquid concentrate is diluted with water, and the droplet size is measured using Dynamic Light Scattering (DLS) or Photon Correlation Spectroscopy (PCS) at room temperature.

- **Droplet Size:** For a formulation to be called a true SNEDDS, the mean hydrodynamic diameter of the oil droplets must consistently remain below 200 nm.

- **Polydispersity Index (PDI):** PDI measures the uniformity of the droplet size distribution in the mixture. A PDI value close to 0 (typically below 0.3) indicates a highly uniform batch where all droplets are roughly the same size. A high PDI means the droplet sizes are erratic, which can lead to unpredictable drug absorption.

4.5 Zeta Potential Measurement

Zeta potential measures the net surface charge on the oil droplets suspended in the emulsion. This value determines whether the nano-droplets will stay separated or clump together during storage or transit.

Researchers measure this charge using a specialized instrument called a Zeta Potential Analyzer.

- A high positive or negative charge, generally greater than +30 mV or less than -30 mV creates strong repulsive forces between the droplets. This repulsion prevents the tiny oil droplets from merging back together, ensuring physical stability.
- If non-ionic surfactants are used, the zeta potential value might be closer to zero, but stability is instead maintained by steric hindrance rather than electrical charge.

4.6 Thermodynamic Stability Studies

To ensure that the liquid SNEDDS concentrate does not break down or separate into layers when exposed to changing environmental conditions, it undergoes three major stress tests:

Heating-Cooling Cycles: The formulation is subjected to alternating temperatures (40°C and 45°C) for six cycles, with storage at each temperature for not less than 48 hours.

Centrifugation: The stable batches from the heating-cooling cycles are centrifuged at 3,000 to 4,000 rpm for 30 minutes.

Freeze-Thaw Cycles: The mixture is exposed to three successive freeze-thaw cycles between -21°C and +25°C, keeping the sample at each temperature for 48 hours. The formulation must show zero phase separation, cracking, or drug precipitation to pass these stability tests.

4.7 Cloud Point Measurement

The cloud point is an essential thermal parameter that defines the exact temperature boundary where the non-ionic surfactant layers within the formulation undergo structural dehydration, causing the isotropic matrix to cloud up and separate into distinct phases. To find this threshold, the liquid SNEDDS pre-concentrate is freshly diluted 100 times using distilled water and slowly heated inside a controlled water bath at a steady rate of 2°C per minute. The temperature at which the clear solution turns turbid or milky is recorded as the cloud point. For oral safety and reliable delivery inside the human gut, the structural cloud point of the optimized formula must remain comfortably above 37°C (preferably exceeding 50°C) to prevent premature phase cracking inside the body.

4.8 Robustness to Dilution

Inside the human body, the formulation will mix with varying amounts of biological fluids. To simulate this variation, the liquid SNEDDS is diluted 10, 100, and 1,000 times with different media, including distilled water, 0.1 N HCl, and simulated intestinal fluid (pH 6.8). The diluted samples are stored for 24 hours and checked to ensure no drug crystals fall out of the solution and no phase separation happens.

5. SOLIDIFICATION TECHNIQUES FOR SNEDDS

While conventional liquid self-nanoemulsifying drug delivery systems (L-SNEDDS) successfully address solubility issues in poorly aqueous-soluble agents, their practical application faces major technological limitations. Encapsulating liquid systems into soft gelatin shells often leads to excipient-capsule component cross-migration, capsule leakage, and physical instabilities like drug precipitation during low-temperature storage. To circumvent these pharmaceutical challenges, converting liquid pre-concentrates into solid state platforms (S-SNEDDS) serves as a robust approach. This solid state modification yields superior chemical protection, scalable downstream processing, higher loading limits, minimal drug precipitation, and excellent bulk flow criteria.

5.1 Selection Strategies for Solidification Approaches

Transforming an isotropic liquid mix into dry, compressible particulate masses demands systemic planning. Formulators select processing techniques based on specific structural criteria:

Excipient Ratios: The overall volume percent of liquid lipids and surfactants present in the mixture dictates carrier mass requirements.

Physicochemical Properties: Thermal sensitivity thresholds, target active molecule solubility, and structural blending compatibilities must be evaluated.

Downstream Compatibility: Selected carriers must remain inert and preserve targeted drug release profiles while exhibiting optimum compressible flow properties.

5.2 Solidification Methods

A. Filling into Hard Gelatin Capsules

One of the most direct engineering pathways involves directly transferring isotropic liquid or semi-solid pre-concentrates into hard gelatin or HPMC capsule bodies. Following the filling operation, a critical processing step called capsule banding or micro-spray sealing is performed around the overlapping body-and-cap junction. This step uses localized hydroalcoholic wetting matrices or thermal bonding mechanisms to generate a hermetic seal. This sealing process prevents fluid leaking during long-term storage and shields internal contents from environmental oxidation.

B. Adsorption onto Solid Porous Carriers

Physical adsorption involves capturing the liquid nano-emulsion matrix within the highly porous internal surface grids of inert, free-flowing powder carriers. The process involves a straightforward laboratory blending technique, typically utilizing a classic mortar and pestle setup or high-shear granulator blades. Under controlled mechanical mixing, the liquid pre-concentrate forms weak van der Waals forces and electrostatic attractions across the carrier's high surface area. This action generates dry, stable particulate systems that can be compressed into tablets or packed into capsules.

C. Spray Drying Technology

Spray drying represents an advanced, highly integrated single-step thermal engineering strategy designed to convert liquid mixtures into micro- or nanoparticulate dry powder matrices. The technical steps involve:

- Feed Solution Preparation: The drug, lipid components, and surfactants are initially dissolved into a single liquid mixture.
- Atomization Step: This liquid feed stream is pumped into a specialized atomizer nozzle system, breaking the solution into highly fine droplet plumes within a heated drying tower chamber.
- Solvent Evaporation: Exposure to hot air or an inert nitrogen gas blanket causes rapid flash evaporation of volatile solvents. This rapid drying traps the

nanoemulsion droplets inside dry, solid carrier particle networks.
- Product Collection: A cyclone separator divides the dry, non-cohesive powder from the exhaust gas stream, delivering a highly uniform solid state product.

D. Melt Granulation Technology

Melt granulation, alternatively identified as thermoplastic granulation, represents a solvent-free, single-step processing configuration widely deployed to convert liquid systems into granular configurations. In this operation, particle agglomeration is driven by adding specialized polymeric or lipid binders that soften or transition into a molten phase at relatively low thermal windows, typically spanning 50°C to 90°C. By completely bypassing organic solvents, this mechanism effectively eliminates the need for post-granulation drying phases, serving as a highly pragmatic substitute for traditional moisture-dependent wet granulation loops. The resulting granular structures exhibit non-swellable, water-insoluble characteristics that remain stable for oral drug delivery applications.

The primary physical mechanisms governing granule development involve:
- Immersion Mechanism: The core solid substrate particles become physically embedded into the surface layers of the melting binder matrix.
- Dispersion Mechanism: The liquefied, low-melting binder spreads uniformly across the peripheral boundaries of individual carrier particles.

As the binder shifts into a molten state, it sets up liquid bridges between adjacent particles, triggering controlled aggregation that yields uniform spherical granules or dense pellets under optimized processing parameters. Generally, the optimal binder concentration falls within a 15% to 25% range, depending strictly on the initial particle surface dimensions and baseline powder flow kinetics. Commonly used adsorbents include neutral solid matrices like silica and magnesium aluminometasilicate, alongside lipid-based carriers such as gelucire and lecithin. Processing typically follows two methods: an in-situ or melt-in procedure where solid binders melt directly within the powder bed during blending, or a spray-on technique where molten binders are introduced onto heated powder beds via a pump setup. Due to the complete exclusion of moisture and subsequent drying phases, this technology is uniquely suited for processing active pharmaceutical ingredients that are highly prone to hydrolytic degradation or thermal instability.

E. Hot Melt Extrusion (HME)

Hot melt extrusion stands as a continuous thermal manufacturing technique utilized to generate solid dispersions with uniform cross-sectional profiles by forcing raw materials through a specific die geometry under high pressure. During HME processing, the continuous input is heated and pressurized within the extruder barrel, causing the polymeric carrier matrix to melt. The active drug molecule and selected polymers undergo high-intensity blending driven by the intense shear forces generated between the rotating twin-screws. As the material moves down the barrel length, combined thermal energy and mechanical shearing facilitate the dispersion of the drug into the molten polymer structure. Upon exiting the terminal die, the extrudate cools rapidly on a downstream conveyor belt, where it can be precisely cut into solid granules or processed into fine powders using a centrifugal milling system.

F. Extrusion-Spheronization

Extrusion-spheronization is a multi-step pelletization approach widely utilized in industrial pharmacy to generate uniform solid oral dosage units such as dense granules, spheroids, and compressed tablets. This strategy is highly effective for converting liquid SNEDDS into structured pellets by blending the liquid pre-concentrate with solid adsorbents, binders, and wet-massing excipients. The process sequence follows:
- **Wet Massing:** The liquid SNEDDS pre-concentrate is thoroughly blended with solid carriers (such as MCC or lactose) to form a wet, cohesive mass.
- **Extrusion:** The plastically deformable wet mass is continuously forced through perforated die screen under controlled temperature and pressure conditions to generate uniform, cylindrical strands.
- **Spheronization:** These cylindrical extrudates are immediately transferred onto the rotating friction plate of a spheronizer. The high frictional forces break the strands and roll them into spherical pellets with uniform particle dimensions, excellent packability, high drug loading capacities, and minimal friability.

G. Freeze-Drying (Lyophilization)

Lyophilization, or cryodesiccating processing, functions as a low-temperature vacuum sublimation dehydration strategy designed to remove water content directly from frozen matrices. Unlike thermal evaporation, freeze-drying effectively protects the structural and chemical stability of the formulation, making it ideal for processing heat-sensitive drugs. The production sequence involves three stages:
- **Freezing Phase:** The liquid formulation or emulsion mixture is cooled to ultra-low temperatures, typically around -50°C, to completely solidify the water matrix.
- **Primary Drying:** Under a deep vacuum environment, the temperature is slightly raised to remove ice crystals through direct sublimation.
- **Secondary Drying:** The system temperature is further modulated to desorb any remaining unfrozen bound moisture molecules, yielding a dry, highly porous, and easily reconstitutable solid SNEDDS powder cake.

H. Supercritical Fluid Extraction Method (SFE)
Supercritical fluid extraction utilizes a gas or fluid held above its critical temperature and pressure boundaries to selectively separate or manipulate targets from solid or liquid substrates. Supercritical carbon dioxide (SC-CO2) is the most dominant extraction agent used due to its non-flammability, low toxicity profile, economical accessibility, and density properties. In this method, the active compounds and excipients are dissolved in an organic phase and then sprayed into the supercritical medium. As the operational pressure and temperature are shifted, the solvent capacity drops rapidly, causing instant precipitation of the encapsulated particles as fine, dry powders with a highly uniform particle size distribution. Prominent (SC-CO2) techniques include Rapid Expansion of Supercritical Solutions (RESS), Gas Antisolvent Recrystallization (GAS), and Solution Enhanced Dispersion by Supercritical Fluids (SEDS).

6. EVALUATION OF SOLID SNEDDS

Converting a liquid isotropic mixture into a solid powder modifies the physical state of the formulation. Therefore, solid SNEDDS (S-SNEDDS) must undergo specific solid-state characterization tests in addition to the standard emulsion evaluation methods. These tests ensure the powder remains stable during storage, flows well during manufacturing, and reconstitutes perfectly inside the body.

6.1 Solid-State Characterization Techniques

These analytical tests verify whether the drug remains completely dissolved in the solid matrix or if it has reverted back to its unabsorbable crystalline form.

6.1.1 Differential Scanning Calorimetry (DSC)

DSC measures heat flow changes to identify the physical state of the drug inside the carrier. Pure hydrophobic drugs display a sharp, distinct endothermic melting peak due to their crystalline structure. When analyzing a successful solid SNEDDS powder, this sharp melting peak completely disappears. This absence confirms that the drug is molecularly dispersed or amorphous within the solid carrier pores.

6.1.2 Powder X-ray Diffraction (PXRD)

PXRD provides structural fingerprints of the formulation components. A pure crystalline drug produces highly intense, sharp diffraction peaks. In contrast, a successful solid SNEDDS formulation displays a diffuse, broad amorphous halo with no sharp peaks. This pattern proves that the crystallization of the drug has been completely suppressed.

6.1.3 Fourier Transform Infrared Spectroscopy (FTIR)

FTIR is used to check for any unwanted chemical reactions between the liquid SNEDDS components and the solid porous carriers. The spectrum of the solid SNEDDS is compared against the spectra of the raw ingredients. The preservation of major functional group bands indicates that the components are chemically compatible.

6.1.4 Scanning Electron Microscopy (SEM)

SEM analysis provides clear microstructural maps to evaluate the surface morphology and particle state of the solid carrier particles before and after loading. While pure porous carriers exhibit clear surface cavities and highly porous microstructures, the optimized solid SNEDDS particles display distinct changes in surface roughness, showing that the fluid components have successfully filled the internal microscopic voids. The complete absence of sharp drug crystal needles on the particle surface confirms successful oil encapsulation.

6.2 Micromeritic and Powder Flow Properties

Before a solid powder can be used in industrial machinery to compress tablets or fill hard capsules, it must exhibit excellent flow behavior. Poor flow leads to weight variations and uneven drug dosing. Formulators evaluate flow using three standard parameters:

- **Angle of Repose:** The powder is allowed to flow through a funnel onto a flat surface to form a cone. The angle formed between the side of the cone and the horizontal ground is measured. An angle below 30°C. indicates excellent flow, while an angle above 40°C. represents poor flow.
- **Hausner's Ratio:** This is the ratio of the tapped density to the bulk density of the powder. A value below 1.25 indicates that the granules flow smoothly.
- **Carr's Compressibility Index:** This percentage value indicates how much a powder can compress. A Carr's index below 15% indicates good flowability, whereas higher values indicate a sticky or cohesive powder that needs optimization.

6.3 Determination of Drug Content and Uniformity

To guarantee that the active pharmaceutical ingredient is uniformly distributed across the solid carrier network and that no major drug loss occurred during the solidification process, a comprehensive drug content analysis is mandatory. An accurately weighed quantity of the optimized solid SNEDDS powder, equivalent to a single standard dose of the active drug molecule, is transferred into a volumetric flask. A suitable organic solvent system such as absolute methanol, acetonitrile, or a specific hydroalcoholic mixture is introduced into the flask to completely extract the trapped drug from the porous carrier grids.

The mixture is subjected to intense mechanical sonication for approximately 15 to 30 minutes to ensure complete drug extraction and rupture of the lipid matrix. Following sonication, the dispersion is centrifuged or passed through a 0.45 µm membrane filter to separate the insoluble carrier fragments from the clear supernatant fluid. The clear filtrate is then appropriately diluted with the respective mobile phase or dissolution media, and the absolute drug concentration is quantified using a

validated UV-Visible spectrophotometer or a high-performance liquid chromatography (HPLC) system. For the batch to pass strict regulatory limits, the calculated drug content must consistently fall within 95% to 105% of the theoretical target.

6.4 In Vitro Dissolution and Drug Release Studies

This test directly demonstrates how much the formulation improves the dissolution rate compared to the pure crystalline drug.

Methodology: The test is carried out using a standard USP Type II (paddle) or USP Type I (basket) dissolution apparatus. The solid SNEDDS powder (or filled capsule) is placed in 900 mL of simulated gastric fluid (0.1N HCl) or Simulated intestinal fluid (pH 6.8) maintained at a strict body temperature of 37 ± 0.5°C. The stirring speed is set between 50 and 100 rpm.

Sampling: Small aliquots of the dissolution fluid are withdrawn at specific time intervals (such as 5, 10, 15, 30, and 60 minutes) and replaced with fresh medium. The samples are passed through a membrane filter to remove any large particles and analyzed using a UV spectrophotometer or HPLC.

Interpretation: While a pure hydrophobic drug typically shows less than 10% to 20% dissolution after an hour, a successful solid SNEDDS formulation should achieve more than 85% to 90% cumulative drug release within the first 15 to 30 minutes, showing a highly accelerated dissolution rate.

7. CONCLUSION AND FUTURE PERSPECTIVES

Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) represent a highly effective and clinically viable formulation strategy to overcome the persistent biopharmaceutical challenges associated with poorly water-soluble drugs. By forming spontaneous, ultra-fine nanoemulsions upon contact with gastrointestinal fluids, these lipid-based platforms significantly enhance the operational surface area, accelerate dissolution kinetics, and facilitate optimal transmucosal absorption paths. The continuous technological transition from conventional liquid pre-concentrates (L-SNEDDS) to solid state configurations (S-SNEDDS) via advanced industrial methods such as melt granulation, hot-melt extrusion, and extrusion-spheronization—successfully bypasses traditional stability limitations, leakage issues, and industrial handling bottlenecks while preserving the intrinsic amorphization benefits of the nanostructured core.

Although challenges regarding surfactant-induced toxicity, precise in vivo-in vitro correlation (IVIVC) mapping, and scale-up engineering complexities persist, strategic excipient selection and robust solid state characterization protocols continue to bridge the gap between laboratory-scale research and commercial production. Looking forward, the integration of advanced mathematical optimization paradigms and biocompatible lipid matrices will further solidify the role of SNEDDS as a versatile vehicle in the global pharmaceutical landscape, offering scalable solutions to optimize the oral bioavailability and therapeutic performance of challenging BCS Class II and Class IV active pharmaceutical ingredients.

REFERENCES

1. Ravi Smitha A, Mohanan J, Kuzhiyil Chali A, Karakkunnummal FN. Advances in Self-Nanoemulsifying Drug Delivery Systems: Mechanistic Insights and Formulation Strategies. J Drug Deliv Ther., 2025; 15(8): 217-236.
2. Zhao Y, Wang C, Hwang AH, Chow P, Ren K, Cong T, Zhang Z, Zheng Y. Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of Zedoary essential oil: Formulation and bioavailability studies. Int J Pharm., 2010; 383(1-2): 170-177.
3. Vinarov Z, Abrahamsson B, Artursson P, Batchelor H, Berben P, Bernkop-Schnürch A, et al. Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Adv Drug Deliv Rev., 2021; 171: 289-331.
4. Namazi NL. Self Nano-Emulsifying Drug Delivery System (SNEDDS) for Cyproterone Acetate: Formulation, Characterization and Pharmacokinetic Evaluation. Results Chem., 2025; 14: 102118.
5. Gallani NS, Dhamai K, Dighade SJ. A Concise Review on Self Nanoemulsifying Drug Delivery System: A Potential Tool to Increase Drug Bioavailability. Int J Pharm Sci Res., 2023; 14(9): 4304-4316.
6. Nasr A, Gardouh AR, Ghorab MM. Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation. Pharmaceutics, 2016; 8(2): 20.
7. Prasanthi D, Meghana G, Navya V. Formulation and Evaluation of Solid-Self Nano Emulsifying Drug Delivery System of Famotidine. Int J Pharm Sci Res., 2021; 12(11): 5785-5799.
8. Lala R, Chande B. Formulation, Optimization and Evaluation of Febuxostat Loaded SNEDDS for Treating Gout. Int J Pharm Sci Res., 2022; 13(6): 2412-2425.
9. Reddy SS, Suresh G. A Self Nanoemulsifying Drug Delivery System for Improvement in Oral Bioavailability of Nimodipine: In Vivo Evaluation. Int J Pharm Sci Res., 2021; 12(11): 5943-5948.
10. Monika, Garg R, Sardana S. Bioavailability Enhancement of Resveratrol Using Self Nanoemulsifying Drug Delivery System Developed Applying Central Composite Design. Int J Pharm Sci Res., 2018; 9(8): 3334-3346.
11. Akiladevi D, Hari Prakash, Biju GB, Madumitha N. Nano-novel Approach: Self Nano Emulsifying Drug

Delivery System (SNEDDS) – Review Article. Res J Pharm Technol, 2020; 13(2).
12. Annisa R, Mutiah R, Yuwono M, Hendradi E. Nanotechnology Approach-Self Nanoemulsifying Drug Delivery System (SNEDDS). Int J Appl Pharm., 2023; 15(4): 12-19.
13. Divate MP, Bawkar SU, Chakole RD, Charde MS. Self Nano-Emulsifying Drug Delivery System: A Review. J Adv Sci Res., 2021; 12(3,2): 1-12.
14. Kumar SV, Janalagadda L, Nannalagadda LP. A Literature Review on Self Nanoemulsifying Drug Delivery System (SNEDDS). Int J Pharm Sci Rev Res., 2021; 70(1): 85-94.
15. Zhao T, Maniglio D, Chen J, Chen B, Motta A, Migliaresi C. Design and optimization of self-nanoemulsifying formulations for lipophilic drugs. Nanotechnology, 2015; 26(12): 12510.
16. Ananya Malgope, Murthy PN, Roja Ramani, Sanjay Dey. Development of nanoemulsion as carrier for transdermal delivery of valsartan. Int J Pharm Chem Sci., 2013; 2(4): 1655-1665.
17. Yu V, Sokolov. Nanoemulsions as prospective drug delivery systems. News Pharmacol, 2014; 1(77): 21-25.
18. Shafiq S, Shakeel F, Talegaonkar S, Ali J, Roop KK, Sanjula B. Formulation development and optimization using nanoemulsion technique: A review. Eur J Pharm Biopharm, 2007; 67(2): E212-E217.
19. Krishnaiah YS. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. J Bioequiv Availab, 2010; 2(2): 28-36.
20. Bhosale RR, Osmani R, Ghodake PP, Shaikh SM, Chavan SR. Nanoemulsion: A review on novel profusion in advanced drug delivery. Indian J Pharm Biol Res., 2014; 2(1): 122-127.
21. Kim HJ, Yoon KA, Hahn M, Park ES, Chi SC. Preparation and in vitro evaluation of self-microemulsifying drug delivery systems containing idebenone. Drug Dev Ind Pharm., 2000; 26(5): 523-529.
22. Anton N, Benoit JP, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates. J Control Release, 2008; 128(3): 185-199.
23. Bouchemal K, Briançon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: Solvent, oil and surfactant optimization. Int J Pharm., 2004; 280(1-2): 241-251.
24. Pouton CW, Porter CJH. Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv Drug Deliv Rev., 2008; 60(6): 625-637.